<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Thin basement membrane nephropathy (benign familial hematuria)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Thin basement membrane nephropathy (benign familial hematuria)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Thin basement membrane nephropathy (benign familial hematuria)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Clifford E Kashtan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brad H Rovin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thin basement membrane nephropathy (TBMN; also called thin basement membrane disease) is considered a relatively common disorder [
         <a href="#rid1">
          1
         </a>
         ]. In most patients, the only abnormal finding on kidney biopsy is diffuse thinning of the glomerular basement membranes (GBM) requiring electron microscopy for the diagnosis [
         <a href="#rid1">
          1-4
         </a>
         ]. Historically, these patients were often described as having benign familial hematuria; however, this terminology is no longer favored and should no longer be used. Some patients given a diagnosis of TBMN also exhibit focal segmental glomerulosclerosis (FSGS) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         TBMN is often familial, with a family history of hematuria being noted in 30 to 50 percent of cases. TBMN seems to account for most cases of what has been called benign familial hematuria. Numerous heterozygous variants in the type IV collagen genes
         <em>
          COL4A3
         </em>
         and
         <em>
          COL4A4
         </em>
         have been identified in patients with TBMN, but such variants are not present in all families [
         <a href="#rid6">
          6
         </a>
         ]. Some clinicians, including the author of this topic, consider hematuria and thin GBM associated with
         <em>
          COL4A3
         </em>
         /
         <em>
          COL4A4
         </em>
         variants to be autosomal dominant Alport syndrome [
         <a href="#rid7">
          7,8
         </a>
         ] and use the term "hematuria with thin glomerular basement membranes" for patients in whom variants in collagen IV genes cannot be identified. A
         <em>
          COL4A5
         </em>
         variant is always diagnostic of X-linked Alport syndrome, regardless of the dimensions of GBM.
        </p>
        <p>
         TBMN will be discussed in this topic review. Alport syndrome is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">
          "Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies on kidneys used for kidney transplantation suggest that the frequency of thin glomerular basement membranes (GBM) in the general population may be as high as 5 to 9 percent [
         <a href="#rid9">
          9,10
         </a>
         ]. However, TBMN is clinically diagnosed in less than 1 percent of the population [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         It had been suspected that the genetic defect in TBMN would be similar to that in hereditary nephritis (Alport syndrome) since patients with the latter group of disorders also have thin glomerular basement membranes (GBM) early in the course of the disease [
         <a href="#rid12">
          12
         </a>
         ]. This hypothesis was confirmed in families in which TBMN was associated with heterozygous variants in
         <em>
          COL4A3
         </em>
         or
         <em>
          COL4A4
         </em>
         , the genes that encode the alpha-3 and alpha-4 chains of type IV collagen, respectively [
         <a href="#rid11">
          11,13-18
         </a>
         ].
        </p>
        <p>
         Patients with TBMN who have heterozygous
         <em>
          COL4A3/COL4A4
         </em>
         variants are considered "carriers" of autosomal recessive Alport syndrome by some clinicians since variants in both alleles of
         <em>
          COL4A3
         </em>
         or
         <em>
          COL4A4
         </em>
         cause autosomal recessive Alport syndrome [
         <a href="#rid19">
          19
         </a>
         ]. Variants in both alleles can be the same (homozygous) or different (compound heterozygous). Approximately 40 to 50 percent of heterozygous carriers of a
         <em>
          COL4A3
         </em>
         or
         <em>
          COL4A4
         </em>
         variant in Alport families exhibit microhematuria [
         <a href="#rid20">
          20-22
         </a>
         ]. However, since a significant percentage of patients with hematuria and heterozygous
         <em>
          COL4A3/COL4A4
         </em>
         variants will have progressive kidney disease, some have argued that they should not be described as "carriers." The finding by exome sequencing of unsuspected
         <em>
          COL4A3
         </em>
         and
         <em>
          COL4A4
         </em>
         variants in patients with chronic kidney disease/end-stage kidney disease highlights the risk of kidney disease progression associated with variants at these loci [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Although both alleles of
         <em>
          COL4A3
         </em>
         or
         <em>
          COL4A4
         </em>
         must be involved to produce autosomal recessive Alport syndrome, TBMN is transmitted in a dominant fashion because the abnormal gene product produces a defect in collagen that is sufficiently severe to interfere with the normal architecture of the GBM, resulting in hematuria. In most cases, however, the heterozygous defect does not provoke the secondary processes that result in the proteinuria, impaired glomerular filtration, and kidney fibrosis observed in patients with Alport syndrome. Genetic modifiers may account for at least some of the variability in outcome in patients with heterozygous
         <em>
          COL4A3
         </em>
         /
         <em>
          COL4A4
         </em>
         variants [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">
          "Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)"
         </a>
         .)
        </p>
        <p>
         Linkage with the
         <em>
          COL4A3
         </em>
         and
         <em>
          COL4A4
         </em>
         genes has not been found in all families with TBMN [
         <a href="#rid25">
          25-27
         </a>
         ]. The underlying defect(s) in these other families are not known. Possibilities include de novo mutations [
         <a href="#rid28">
          28
         </a>
         ], incomplete penetrance, or novel genetic loci.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL CHARACTERISTICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         TBMN is often familial, with pedigrees exhibiting an autosomal dominant pattern [
         <a href="#rid2">
          2
         </a>
         ]. A family history of hematuria is noted in 30 to 50 percent of cases.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Microscopic hematuria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The characteristic manifestation of TBMN is persistent or intermittent asymptomatic microscopic hematuria incidentally discovered on routine urinalysis [
         <a href="#rid1">
          1
         </a>
         ]. It has been proposed that red cells enter Bowman's space in TBMN by moving through localized, transient ruptures in the glomerular capillary wall [
         <a href="#rid29">
          29
         </a>
         ]. This may represent an exaggeration of the normal process of naturally occurring spontaneous ruptures in the glomerular basement membrane (GBM) [
         <a href="#rid30">
          30
         </a>
         ]. Such ruptures may also account for the small number of red cells excreted in normal urine.
        </p>
        <p>
         As in other glomerular diseases, dysmorphic red cells and, in some patients, red blood cell casts can be seen on examination of the urine sediment in patients with TBMN [
         <a href="#rid11">
          11,31
         </a>
         ]. Episodes of macroscopic hematuria may occur. (See
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults", section on 'Glomerular versus nonglomerular bleeding'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3112.html" rel="external">
          "IgA nephropathy: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Gross hematuria and flank pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with TBMN may have episodes of gross (macroscopic) hematuria. These episodes may be preceded by an upper respiratory tract infection, simulating poststreptococcal glomerulonephritis and immunoglobulin A (IgA) nephropathy [
         <a href="#rid2">
          2,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults"
         </a>
         .)
        </p>
        <p>
         Gross hematuria in TBMN may be associated with flank (loin) pain, simulating the clinical picture of loin pain-hematuria syndrome [
         <a href="#rid11">
          11,32,33
         </a>
         ]. These episodes are often associated with hypercalciuria and/or hyperuricosuria, which are risk factors for both stone formation and hematuria. (See
         <a class="medical medical_review" href="/z/d/html/7203.html" rel="external">
          "Loin pain-hematuria syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">
          "Kidney stones in adults: Epidemiology and risk factors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults"
         </a>
         .)
        </p>
        <p>
         These relationships were illustrated in a study of 46 individuals with biopsy-proven TBMN or first-degree relatives with persistent microscopic hematuria in which the following findings were noted [
         <a href="#rid33">
          33
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eighteen (39 percent) had hypercalciuria and/or hyperuricosuria, which are important risk factors for nephrolithiasis, and 25 percent of those with proven disease had a history of previous nephrolithiasis. These values were much higher than in patients with IgA nephropathy or normal controls (eg, 3 percent of IgA nephropathy patients had a history of nephrolithiasis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The TBMN patients and microhematuric first-degree relatives with hypercalciuria and/or hyperuricosuria had, when compared with those with normal calcium and uric acid excretion, significantly higher rates of episodes of gross hematuria (44 versus 7 percent) and episodes of loin pain (27 versus 3 percent).
        </p>
        <p>
        </p>
        <p>
         Thus, renal tubular injury and obstruction may be promoted by the simultaneous presence of red cells and microcrystals in the tubular lumen.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Acute kidney injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         A case report described the development of acute kidney injury and gross hematuria developing after over-anticoagulation with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (international normalized ratio [INR] 3.6 versus prior values of 1.7 to 1.8) [
         <a href="#rid34">
          34
         </a>
         ]. Kidney biopsy showed, in addition to thin GBM, distension of many renal tubules by intratubular red cells and tubular cell injury consistent with acute tubular necrosis. The patient required hemodialysis for six weeks, and the serum creatinine had returned to close to baseline levels (1.3 versus 1.0 mg/dL at baseline [115 versus 88 micromol/L]) at six months.
        </p>
        <p>
         Acute kidney injury associated with gross hematuria with similar pathologic findings and clinical course have been described in patients with IgA nephropathy independent of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         therapy.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Other kidney manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urinary protein excretion and blood pressure are typically normal in patients with TBMN. However, some patients have minimal to moderate proteinuria (usually less than 1.5 g/day, rarely in the nephrotic range) and/or hypertension [
         <a href="#rid2">
          2-4,18,22,35-37
         </a>
         ]. Such patients may have unrecognized Alport syndrome, represent a more severe phenotype of TBMN, or have another gene polymorphism influencing their course.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of TBMN is usually inferred from the benign presentation and course, the positive family history of hematuria, and the negative family history of kidney failure. Kidney biopsy is generally
         <strong>
          not
         </strong>
         performed in patients who present with familial isolated glomerular hematuria, no or minimal proteinuria, normal kidney function, and no family history of kidney failure. The prognosis is excellent in such patients unless the clinical manifestations progress, as occurs in all males and some females with Alport syndrome, as well as many patients with IgA nephropathy. (See
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Indications for kidney biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that kidney biopsy generally be limited to patients with suspected TBMN who also have proteinuria. There are, however, some settings in which kidney biopsy might be considered in patients with hematuria alone:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is the patient being considered as a kidney donor?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is conception with another individual with isolated hematuria being planned?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is there an issue concerning the purchase of life or disability insurance?
        </p>
        <p>
        </p>
        <p>
         Kidney biopsy reveals diffuse thinning of the glomerular basement membrane (GBM) on electron microscopy (GBM width usually between 150 and 225 nm, versus 300 to 400 nm in normal subjects)  (
         <a class="graphic graphic_picture graphicRef55486" href="/z/d/graphic/55486.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid1">
          1-4
         </a>
         ]; notably, normal values for GBM width are age and sex dependent [
         <a href="#rid9">
          9,38
         </a>
         ]. TBMN requires electron microscopy for histologic diagnosis; it cannot be diagnosed by examination of the biopsy specimen by light microscopy alone.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         TBMN must be distinguished from other glomerular causes of isolated hematuria such as IgA nephropathy and C3 glomerulopathy. Clear differentiation between TBMN and Alport syndrome is often difficult, especially in pediatric patients and in patients with heterozygous
         <em>
          COL4A3
         </em>
         /
         <em>
          COL4A4
         </em>
         variants. TBMN and IgA nephropathy are considered the most common disorders underlying asymptomatic hematuria, together accounting for 50 percent or more of cases [
         <a href="#rid39">
          39,40
         </a>
         ]. In these studies, an unknown percentage of patients diagnosed with TBMN may have had Alport syndrome since genetic testing was not routinely performed.
        </p>
        <p>
         The history and clinical presentation are often helpful in distinguishing between these disorders [
         <a href="#rid3">
          3,41
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/3053.html" rel="external">
          "Isolated and persistent glomerular hematuria in adults"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with IgA nephropathy do not typically have a family history of kidney disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with Alport syndrome frequently have a family history of kidney failure, most often affecting males since most kindreds have X-linked inheritance. The next section reviews this distinction in more detail.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Distinction from Alport syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         In view of the similarities in early histologic changes and in pathogenesis, TBMN may be difficult to distinguish from Alport syndrome in many cases. The following clinical and histologic parameters may help in establishing the correct diagnosis (see
         <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">
          "Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening first-degree relatives for hematuria often suggests the diagnosis of TBMN. In view of its autosomal dominant inheritance, roughly 50 percent of first-degree relatives should have hematuria [
         <a href="#rid10">
          10,31
         </a>
         ]. Father-to-son transmission may be present, a finding that is not seen in X-linked Alport syndrome but may occur in autosomal dominant Alport syndrome. Next-generation sequencing studies have indicated that autosomal dominant Alport syndrome is significantly more common than previously thought, and, therefore, the presence of father-to-son transmission does not reliably exclude a diagnosis of Alport syndrome [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with TBMN rarely have hearing loss, ocular abnormalities, or a prominent family history of kidney failure [
         <a href="#rid44">
          44
         </a>
         ]. With X-linked and autosomal recessive Alport syndrome, hearing loss is often observed in childhood, but ocular abnormalities may not be evident until the third decade of life [
         <a href="#rid11">
          11
         </a>
         ]. The absence of hearing loss and ocular abnormalities does not exclude a diagnosis of Alport syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Where available, immunohistology of skin biopsy specimens may be a direct way to distinguish between these disorders [
         <a href="#rid45">
          45
         </a>
         ]. Incubation of the biopsy specimen with a monoclonal antibody directed against the alpha-5 chain of type IV collagen (which is the site of the primary abnormality in X-linked Alport syndrome) shows no staining along the epidermal basement membrane in approximately 80 percent of males with X-linked Alport syndrome, discontinuous staining in 60 to 70 percent of females with X-linked Alport syndrome, and normal staining in individuals with TBMN. Since some patients with X-linked Alport syndrome and all patients with autosomal recessive and autosomal dominant Alport syndrome have normal epidermal basement membrane staining for the alpha-5(IV) chain, this test can confirm a suspected diagnosis of X-linked Alport syndrome, but it cannot by itself exclude the diagnosis of any form of Alport syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although kidney biopsy may reveal thin GBM as the only abnormality in children and women with X-linked Alport syndrome or autosomal recessive Alport syndrome [
         <a href="#rid12">
          12
         </a>
         ], incubation of kidney tissue with antibodies against the alpha-3, -4, and -5 chains of type IV collagen reveals abnormalities of GBM staining in the majority of patients (but shows normal staining in TBMN) [
         <a href="#rid11">
          11,44
         </a>
         ]. However, normal immunostaining of GBMs for the alpha-3, -4, and -5 chains of type IV collagen does not exclude a diagnosis of Alport syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Molecular testing for
         <em>
          COL4A3
         </em>
         ,
         <em>
          COL4A4
         </em>
         , and
         <em>
          COL4A5
         </em>
         variants by next-generation sequencing is a valuable addition to the diagnostic menu for familial hematurias [
         <a href="#rid41">
          41
         </a>
         ]. In some centers, next-generation sequencing is replacing kidney biopsy in the evaluation of possible familial hematuria, especially where insurance coverage does not represent a significant barrier.
        </p>
        <p>
        </p>
        <p>
         Immunostaining may not be necessary in all patients with suspected TBMN. Such staining is not required, for example, in the patient with isolated hematuria and thin GBM who has a positive family history of hematuria but a negative history for kidney failure. By comparison, immunostaining should be considered in sporadic cases (ie, patients who have no relatives with hematuria), in patients with thin GBM and a family history of kidney failure, and in patients with thin GBM and elevated urine protein levels. In patients with suspected TBMN, the normal expression of type IV collagen alpha chains in the GBM provides supportive evidence but cannot entirely exclude Alport syndrome. Again, it should be noted that at some centers, genetic evaluation by next-generation sequencing is replacing kidney biopsy with immunostaining for evaluation of possible familial hematuria.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          COURSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The long-term prognosis is good in most patients with isolated hematuria and thin glomerular basement membranes (GBM) [
         <a href="#rid2">
          2,3,46
         </a>
         ]. However, the presence of a heterozygous
         <em>
          COL4A3
         </em>
         /
         <em>
          COL4A4
         </em>
         variant in a patient with hematuria and thin GBM should be considered a risk factor for chronic kidney disease, whether a clinician decides to diagnosis the patient with Alport syndrome or TBMN. Slowly progressive kidney function impairment can occur and is often manifested on kidney biopsy by focal segmental glomerulosclerosis (FSGS) [
         <a href="#rid2">
          2,3,10
         </a>
         ].
        </p>
        <p>
         It has been unclear whether TBMN was responsible for the progressive glomerular injury or was an incidental finding in patients with underlying FSGS. In one study, for example, the incidence of TBMN in all patients with biopsy-proven FSGS was 5 percent, similar to that in the general population [
         <a href="#rid10">
          10
         </a>
         ]. In addition, some patients with thin GBM and progressive kidney dysfunction actually have Alport syndrome [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         However, some data suggest that FSGS is frequently caused by
         <em>
          COL4A3
         </em>
         /
         <em>
          COL4A4
         </em>
         variants:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study of 116 patients from 13 Greek-Cypriot families identified 20 with biopsy-proven FSGS and TBMN [
         <a href="#rid5">
          5
         </a>
         ]. The 20 patients had chronic kidney disease of varying severity, with some developing end-stage kidney disease. However, kidney dysfunction was not confined to those with FSGS; 11 additional patients with a specific variant in the
         <em>
          COL4A3
         </em>
         or
         <em>
          COL4A4
         </em>
         genes but without FSGS also developed chronic kidney disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study of 70 families with a diagnosis of hereditary FSGS found that 7 families had heterozygous
         <em>
          COL4A3
         </em>
         /
         <em>
          COL4A4
         </em>
         variants [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Collagen IV variants were identified in 38 percent of families with "familial FSGS" and in 3 percent of adults with sporadic FSGS [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         These findings are not surprising, since it has long been known that FSGS is a frequent histological finding in Alport patients with proteinuria.
        </p>
        <p>
         These data suggest that either the presence of proteinuria or a positive family history of chronic kidney disease may portend a less benign prognosis for individuals diagnosed with TBMN [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         The great majority of people with isolated hematuria, TBMN, and negative family history for kidney failure maintain normal kidney function and normal urine protein excretion on follow-up. However, in our view, follow-up is essential in order to identify those individuals who, for whatever reason, exhibit a progressive disease course.
        </p>
        <p>
         The frequency of thin GBM in the general population means that it will often be found as an incidental finding in other kidney diseases such as diabetic nephropathy, lupus nephritis, membranous glomerulopathy, minimal change disease, and IgA nephropathy [
         <a href="#rid10">
          10
         </a>
         ]. In diabetic nephropathy, for example, TBMN may be responsible for otherwise unexplained hematuria [
         <a href="#rid51">
          51
         </a>
         ]. It has been suggested that TBMN may occur with slightly increased frequency in patients with IgA nephropathy, particularly among those with a family history of IgA nephropathy [
         <a href="#rid46">
          46
         </a>
         ]. It is unclear whether there is a true relationship between these disorders or whether thin GBM might increase the severity of concurrent IgA nephropathy. Collagen IV gene sequencing may be indicated in some of these patients since dual nephropathies have been described in some patients with Alport syndrome.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         One study has shown that angiotensin blockade can delay end-stage kidney disease in patients with heterozygous variants in
         <em>
          COL4A3
         </em>
         ,
         <em>
          COL4A4
         </em>
         , or
         <em>
          COL4A5
         </em>
         [
         <a href="#rid52">
          52
         </a>
         ]. Based on these findings and upon benefits observed in patients with proteinuria and other forms of chronic kidney disease, we suggest the administration of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker in adults with TBMN who also have
         <strong>
         </strong>
         proteinuria (above 500 to 1000 mg/day), particularly if they also have elevated blood pressure and/or an elevation in serum creatinine or reduction in estimated glomerular filtration rate. Both the proteinuria and blood pressure goals should be the same as those in other forms of proteinuric chronic kidney disease. (See
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Proteinuria goal'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Blood pressure goal'
         </a>
         .)
        </p>
        <p>
         As noted above, occasional patients have recurrent episodes of gross hematuria and/or flank pain. The administration of an ACE inhibitor may be beneficial in this setting, perhaps by lowering the intraglomerular pressure [
         <a href="#rid32">
          32
         </a>
         ]. In addition, treating hypercalciuria or hyperuricosuria, if present, has reduced hematuria in other patients [
         <a href="#rid53">
          53,54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2915583755">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">
          "Society guideline links: Glomerular disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30884403">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15354.html" rel="external">
          "Patient education: Blood in the urine (hematuria) in adults (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/83247.html" rel="external">
          "Patient education: Blood in the urine (hematuria) in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4412.html" rel="external">
          "Patient education: Blood in the urine (hematuria) in adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4425.html" rel="external">
          "Patient education: Glomerular disease (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Thin basement membrane nephropathy (TBMN) is considered a common disorder. Although thin glomerular basement membranes (GBM) can be seen in 5 to 9 percent of biopsy specimens, it is clinically diagnosed in less than 1 percent of the population. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Heterozygous variants in
         <em>
          COL4A3
         </em>
         or
         <em>
          COL4A4
         </em>
         , the genes that encode for the alpha-3 and alpha-4 chains of type IV collagen, are responsible for this disorder in 40 to 50 percent of affected families. Patients with these heterozygous variants are considered by some to be "carriers" of autosomal recessive Alport syndrome since variants in both alleles of
         <em>
          COL4A3
         </em>
         or
         <em>
          COL4A4
         </em>
         cause autosomal recessive Alport syndrome. Others, including the author of this topic, regard these patients as having autosomal dominant Alport syndrome. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – A family history of hematuria is noted in 30 to 50 percent of cases, most commonly with autosomal dominant inheritance. The characteristic manifestation of TBMN is persistent or intermittent asymptomatic glomerular hematuria. Most frequently, urinary protein excretion, blood pressure, and kidney function are normal. Some patients have minimal to moderate proteinuria (usually less than 1.5 g/day, rarely in the nephrotic range) and/or hypertension. The invariable finding on kidney biopsy with TBMN is diffuse thinning of the GBM on electron microscopy. GBM thinning is frequently observed in patients with Alport syndrome, so the finding of thin GBM in and of itself is of limited prognostic utility. (See
         <a class="local">
          'Clinical characteristics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis is usually inferred from the benign presentation and course, the positive family history of hematuria, and the negative family history of kidney failure. Kidney biopsy is generally
         <strong>
          not
         </strong>
         performed in such patients. However, we suggest the performance of a kidney biopsy in adults with suspected TBMN (eg, glomerular hematuria)
         <strong>
          plus
         </strong>
         proteinuria (defined as greater than 500 to 1000 mg/day). TBMN must be distinguished from the other common glomerular causes of isolated hematuria: immunoglobulin A (IgA) nephropathy and Alport syndrome. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Long-term prognosis is generally good. However, slowly progressive kidney function impairment can occur and is often manifested on kidney biopsy by focal segmental glomerulosclerosis (FSGS). Follow-up is essential to identify those individuals who exhibit a progressive disease course. (See
         <a class="local">
          'Course'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Among patients with TBMN
         <strong>
          plus
         </strong>
         proteinuria (greater than 500 to 1000 mg/day), we suggest the administration of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). In such patients, we suggest that both the proteinuria and blood pressure goals should be the same as those in other forms of proteinuric chronic kidney disease. These issues are discussed elsewhere. (See
         <a class="local">
          'Treatment'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Tryggvason K, Patrakka J. Thin basement membrane nephropathy. J Am Soc Nephrol 2006; 17:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aarons I, Smith PS, Davies RA, et al. Thin membrane nephropathy: a clinico-pathological study. Clin Nephrol 1989; 32:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiebosch AT, Frederik PM, van Breda Vriesman PJ, et al. Thin-basement-membrane nephropathy in adults with persistent hematuria. N Engl J Med 1989; 320:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thin-membrane nephropathy--how thin is thin? Lancet 1990; 336:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voskarides K, Damianou L, Neocleous V, et al. COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol 2007; 18:3004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rana K, Wang YY, Powell H, et al. Persistent familial hematuria in children and the locus for thin basement membrane nephropathy. Pediatr Nephrol 2005; 20:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashtan C. Alport syndrome: facts and opinions. F1000Res 2017; 6:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int 2018; 93:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dische FE, Anderson VE, Keane SJ, et al. Incidence of thin membrane nephropathy: morphometric investigation of a population sample. J Clin Pathol 1990; 43:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosio FG, Falkenhain ME, Sedmak DD. Association of thin glomerular basement membrane with other glomerulopathies. Kidney Int 1994; 46:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savige J, Rana K, Tonna S, et al. Thin basement membrane nephropathy. Kidney Int 2003; 64:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rumpelt HJ. Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations. Clin Nephrol 1980; 13:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemmink HH, Nillesen WN, Mochizuki T, et al. Benign familial hematuria due to mutation of the type IV collagen alpha4 gene. J Clin Invest 1996; 98:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buzza M, Wang YY, Dagher H, et al. COL4A4 mutation in thin basement membrane disease previously described in Alport syndrome. Kidney Int 2001; 60:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badenas C, Praga M, Tazón B, et al. Mutations in theCOL4A4 and COL4A3 genes cause familial benign hematuria. J Am Soc Nephrol 2002; 13:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buzza M, Dagher H, Wang YY, et al. Mutations in the COL4A4 gene in thin basement membrane disease. Kidney Int 2003; 63:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348:2543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frascà GM, Onetti-Muda A, Mari F, et al. Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis--a collaborative study of the Italian Renal Immunopathology Group. Nephrol Dial Transplant 2005; 20:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mochizuki T, Lemmink HH, Mariyama M, et al. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 1994; 8:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boye E, Mollet G, Forestier L, et al. Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome. Am J Hum Genet 1998; 63:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heidet L, Arrondel C, Forestier L, et al. Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol 2001; 12:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torra R, Tazón-Vega B, Ars E, Ballarín J. Collagen type IV (alpha3-alpha4) nephropathy: from isolated haematuria to renal failure. Nephrol Dial Transplant 2004; 19:2429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic Utility of Exome Sequencing for Kidney Disease. N Engl J Med 2019; 380:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voskarides K, Stefanou C, Pieri M, et al. A functional variant in NEPH3 gene confers high risk of renal failure in primary hematuric glomerulopathies. Evidence for predisposition to microalbuminuria in the general population. PLoS One 2017; 12:e0174274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito A, Yamazaki H, Nakagawa Y, Arakawa M. Molecular genetics of renal diseases. Intern Med 1997; 36:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashtan CE. Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 1998; 9:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buzza M, Wilson D, Savige J. Segregation of hematuria in thin basement membrane disease with haplotypes at the loci for Alport syndrome. Kidney Int 2001; 59:1670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang YY, Rana K, Tonna S, et al. COL4A3 mutations and their clinical consequences in thin basement membrane nephropathy (TBMN). Kidney Int 2004; 65:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collar JE, Ladva S, Cairns TD, Cattell V. Red cell traverse through thin glomerular basement membranes. Kidney Int 2001; 59:2069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schurek HJ. Mechanisms of glomerular proteinuria and hematuria. Kidney Int Suppl 1994; 47:S12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumenthal SS, Fritsche C, Lemann J Jr. Establishing the diagnosis of benign familial hematuria. The importance of examining the urine sediment of family members. JAMA 1988; 259:2263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebert LA, Betts JA, Sedmak DD, et al. Loin pain-hematuria syndrome associated with thin glomerular basement membrane disease and hemorrhage into renal tubules. Kidney Int 1996; 49:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Praga M, Martínez MA, Andrés A, et al. Association of thin basement membrane nephropathy with hypercalciuria, hyperuricosuria and nephrolithiasis. Kidney Int 1998; 54:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abt AB, Carroll LE, Mohler JH. Thin basement membrane disease and acute renal failure secondary to gross hematuria and tubular necrosis. Am J Kidney Dis 2000; 35:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auwardt R, Savige J, Wilson D. A comparison of the clinical and laboratory features of thin basement membrane disease (TBMD) and IgA glomerulonephritis (IgA GN). Clin Nephrol 1999; 52:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall CL, Bradley R, Kerr A, et al. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol 2004; 62:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pettersson E, Törnroth T, Wieslander J. Abnormally thin glomerular basement membrane and the Goodpasture epitope. Clin Nephrol 1990; 33:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogler C, McAdams AJ, Homan SM. Glomerular basement membrane and lamina densa in infants and children: an ultrastructural evaluation. Pediatr Pathol 1987; 7:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Paassen P, van Breda Vriesman PJ, van Rie H, Tervaert JW. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int 2004; 66:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iseki K, Miyasato F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int 2004; 66:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savige J, Gregory M, Gross O, et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 2013; 24:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fallerini C, Dosa L, Tita R, et al. Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet 2014; 86:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morinière V, Dahan K, Hilbert P, et al. Improving mutation screening in familial hematuric nephropathies through next generation sequencing. J Am Soc Nephrol 2014; 25:2740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieuwhof CM, de Heer F, de Leeuw P, van Breda Vriesman PJ. Thin GBM nephropathy: premature glomerular obsolescence is associated with hypertension and late onset renal failure. Kidney Int 1997; 51:1596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshioka K, Hino S, Takemura T, et al. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. Am J Pathol 1994; 144:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chrystomou A, Kincaid-Smith P, Becker G. Clinical features and prognosis of thin basement membrane disease (abstract). J Am Soc Nephrol 1993; 4:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knebelmann B, Breillat C, Forestier L, et al. Spectrum of mutations in the COL4A5 collagen gene in X-linked Alport syndrome. Am J Hum Genet 1996; 59:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malone AF, Phelan PJ, Hall G, et al. Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. Kidney Int 2014; 86:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gast C, Pengelly RJ, Lyon M, et al. Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 2016; 31:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashtan CE. The wages of thin. J Am Soc Nephrol 2007; 18:2800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsumae T, Fukusaki M, Sakata N, et al. Thin glomerular basement membrane in diabetic patients with urinary abnormalities. Clin Nephrol 1994; 42:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Temme J, Peters F, Lange K, et al. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int 2012; 81:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andres A, Praga M, Bello I, et al. Hematuria due to hypercalciuria and hyperuricosuria in adult patients. Kidney Int 1989; 36:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Praga M, Alegre R, Hernández E, et al. Familial microscopic hematuria caused by hypercalciuria and hyperuricosuria. Am J Kidney Dis 2000; 35:141.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3038 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16467446" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Thin basement membrane nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2805457" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Thin membrane nephropathy: a clinico-pathological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2909874" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Thin-basement-membrane nephropathy in adults with persistent hematuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1974992" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Thin-membrane nephropathy--how thin is thin?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942953" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16235097" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Persistent familial hematuria in children and the locus for thin basement membrane nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28163907" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Alport syndrome: facts and opinions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29551517" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Alport syndrome: a unified classification of genetic disorders of collagen IVα345: a position paper of the Alport Syndrome Classification Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2380394" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Incidence of thin membrane nephropathy: morphometric investigation of a population sample.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7967360" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Association of thin glomerular basement membrane with other glomerulopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12969134" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Thin basement membrane nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7398144" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8787673" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Benign familial hematuria due to mutation of the type IV collagen alpha4 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11473630" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : COL4A4 mutation in thin basement membrane disease previously described in Alport syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11961012" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Mutations in theCOL4A4 and COL4A3 genes cause familial benign hematuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12631110" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mutations in the COL4A4 gene in thin basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12815141" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Alport's syndrome, Goodpasture's syndrome, and type IV collagen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15618242" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis--a collaborative study of the Italian Renal Immunopathology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7987396" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9792860" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11134255" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15280517" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Collagen type IV (alpha3-alpha4) nephropathy: from isolated haematuria to renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30586318" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Diagnostic Utility of Exome Sequencing for Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28334007" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A functional variant in NEPH3 gene confers high risk of renal failure in primary hematuric glomerulopathies. Evidence for predisposition to microalbuminuria in the general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9099587" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Molecular genetics of renal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9727383" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Alport syndrome and thin glomerular basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11318937" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Segregation of hematuria in thin basement membrane disease with haplotypes at the loci for Alport syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14871398" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : COL4A3 mutations and their clinical consequences in thin basement membrane nephropathy (TBMN).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11380808" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Red cell traverse through thin glomerular basement membranes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7869660" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Mechanisms of glomerular proteinuria and hematuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3352118" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Establishing the diagnosis of benign familial hematuria. The importance of examining the urine sediment of family members.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8770964" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Loin pain-hematuria syndrome associated with thin glomerular basement membrane disease and hemorrhage into renal tubules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9734616" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Association of thin basement membrane nephropathy with hypercalciuria, hyperuricosuria and nephrolithiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10692282" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Thin basement membrane disease and acute renal failure secondary to gross hematuria and tubular necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10442488" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A comparison of the clinical and laboratory features of thin basement membrane disease (TBMD) and IgA glomerulonephritis (IgA GN).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15524056" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2182229" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Abnormally thin glomerular basement membrane and the Goodpasture epitope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3449814" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Glomerular basement membrane and lamina densa in infants and children: an ultrastructural evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327380" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327381" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Outcome study of renal biopsy patients in Okinawa, Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23349312" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24033287" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24854265" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Improving mutation screening in familial hematuric nephropathies through next generation sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9150478" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Thin GBM nephropathy: premature glomerular obsolescence is associated with hypertension and late onset renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8178947" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Clinical features and prognosis of thin basement membrane disease (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8940267" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Spectrum of mutations in the COL4A5 collagen gene in X-linked Alport syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25229338" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26346198" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942944" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The wages of thin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7834913" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Thin glomerular basement membrane in diabetic patients with urinary abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22237748" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2811059" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Hematuria due to hypercalciuria and hyperuricosuria in adult patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10620556" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Familial microscopic hematuria caused by hypercalciuria and hyperuricosuria.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
